Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

Information
References
Discussion
Files

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study - RWTH-CONV-248314

Main document file(s):

Similar records

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines